Published in Dement Geriatr Cogn Disord on July 03, 2014
Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease. BMC Neurol (2014) 0.82
The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan. PLoS One (2015) 0.75
Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression. Dement Geriatr Cogn Dis Extra (2017) 0.75
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol (2006) 9.99
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet (2006) 5.34
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry (2012) 2.68
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol (2012) 2.39
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol (2012) 2.22
Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord (2007) 2.15
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2009) 2.10
Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol (2003) 1.99
Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 1.86
Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord (2007) 1.76
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry (2009) 1.72
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett (2007) 1.54
CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies. J Neurol Neurosurg Psychiatry (2010) 1.50
Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol (2008) 1.48
Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. Biol Psychiatry (2011) 1.43
Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol (2007) 1.36
Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol (2010) 1.35
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 1.30
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Res (2010) 1.22
CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One (2012) 1.21
Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist (2010) 1.20
Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol (2005) 1.16
Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology (2012) 1.16
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis (2010) 1.14
Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease. Alzheimer Dis Assoc Disord (2007) 1.13
Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2007) 1.12
Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS One (2013) 1.10
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull (2003) 1.10
Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One (2010) 1.10
Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One (2012) 1.09
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology (2015) 1.07
Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.06
Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int J Geriatr Psychiatry (2010) 1.06
Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging (2008) 1.05
Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2009) 1.04
Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord (2006) 1.03
Patients with Lewy body dementia use more resources than those with Alzheimer's disease. Int J Geriatr Psychiatry (2007) 1.01
Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One (2013) 1.01
No diagnostic value of plasma clusterin in Alzheimer's disease. PLoS One (2012) 1.01
Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech Ageing Dev (2010) 1.00
Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. Eur Neurol (2010) 0.99
Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther (2011) 0.99
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging (2012) 0.98
Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease. Neuromolecular Med (2012) 0.98
C4b-binding protein in Alzheimer's disease: binding to Abeta1-42 and to dead cells. Mol Immunol (2008) 0.97
Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord (2011) 0.97
Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis (2013) 0.97
Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2008) 0.97
Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. J Alzheimers Dis (2012) 0.96
Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals. BMC Geriatr (2012) 0.96
Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol (2014) 0.96
Altered CSF orexin and α-synuclein levels in dementia patients. J Alzheimers Dis (2012) 0.96
A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis (2013) 0.95
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. Clin Interv Aging (2013) 0.94
The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One (2012) 0.92
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. Int J Mol Med (2007) 0.92
Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis (2012) 0.91
SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol Neurodegener (2014) 0.90
Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement Geriatr Cogn Disord (2008) 0.90
Association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiol Aging (2010) 0.89
Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Res (2013) 0.89
A Quick Test for Cognitive Speed: a measure of cognitive speed in dementia with Lewy bodies. Am J Alzheimers Dis Other Demen (2007) 0.89
Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. J Clin Psychiatry (2010) 0.89
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurol (2014) 0.89
Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis (2010) 0.88
A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. Alzheimers Res Ther (2010) 0.88